Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the Multidrug-resistant Tuberculosis Pandemic; an Open Label Phase I Clinical Trial of the Therapeutic TB H56:IC31 Vaccine and Cyclooxygenase-inhibitors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etoricoxib (Primary) ; H56IC (Primary)
Indications Pulmonary tuberculosis
Focus Adverse reactions; Pharmacodynamics
Acronyms TBCOX2

Most Recent Events

07 Apr 2022 Status changed from active, no longer recruiting to completed.
15 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Sep 2019.
15 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Sep 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight